David A. Siegel Ionis Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,040,111 shares of IONS stock, worth $49.6 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

1,040,111

Previous 777,011 33.86%

Holding current value

$49.6 Million

Previous $39.3 Million 14.7%

% of portfolio

0.11%

Previous 0.09%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $11.1 Million - $14.1 Million	263,100 Added 33.86%	1,040,111 $45.1 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $7.49 Million - $8.92 Million	172,700 Added 28.58%	777,011 $39.3 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $10 Million - $12.3 Million	260,100 Added 75.56%	604,311 $27.4 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $55,567 - $69,328	-1,600 Reduced 0.46%	344,211 $14.1 Million
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $9.71 Million - $11.9 Million	-289,100 Reduced 45.53%	345,811 $12.4 Million

Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $838,912 - $1.05 Million	-22,600 Reduced 3.44%	634,911 $24 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $1.76 Million - $2.35 Million	-48,300 Reduced 6.84%	657,511 $29.1 Million
Q2 2022 Aug 15, 2022	BUY	$31.71 - $43.0 $2.99 Million - $4.05 Million	94,200 Added 15.4%	705,811 $26.1 Million
Q1 2022 May 16, 2022	BUY	$29.88 - $37.04 $3.41 Million - $4.23 Million	114,200 Added 22.96%	611,611 $22.7 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $1.67 Million - $2.29 Million	65,200 Added 15.09%	497,411 $15.1 Million
Q3 2021 Nov 15, 2021	SELL	$33.54 - $40.55 $3.14 Million - $3.8 Million	-93,600 Reduced 17.8%	432,211 $14.5 Million
Q2 2021 Aug 16, 2021	SELL	$34.54 - $47.25 $6.51 Million - $8.91 Million	-188,600 Reduced 26.4%	525,811 $21 Million
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $3.65 Million - $5.47 Million	-85,800 Reduced 10.72%	714,411 $32.1 Million
Q4 2020 Feb 16, 2021	SELL	$45.3 - $60.27 $13.1 Million - $17.5 Million	-289,900 Reduced 26.59%	800,211 $45.2 Million
Q3 2020 Nov 16, 2020	SELL	$47.45 - $62.95 $3.87 Million - $5.14 Million	-81,600 Reduced 6.96%	1,090,111 $51.7 Million
Q2 2020 Aug 14, 2020	SELL	$46.85 - $61.05 $726,175 - $946,275	-15,500 Reduced 1.31%	1,171,711 $69.1 Million
Q1 2020 May 15, 2020	SELL	$41.6 - $63.4 $7.47 Million - $11.4 Million	-179,600 Reduced 13.14%	1,187,211 $56.1 Million
Q4 2019 Feb 14, 2020	SELL	$53.85 - $65.27 $13.3 Million - $16.2 Million	-247,600 Reduced 15.34%	1,366,811 $82.6 Million
Q3 2019 Nov 14, 2019	SELL	$59.06 - $72.15 $1.2 Million - $1.46 Million	-20,300 Reduced 1.24%	1,614,411 $96.7 Million
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $51.4 Million - $71.3 Million	827,800 Added 102.59%	1,634,711 $105 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $10.6 Million - $16.2 Million	200,000 Added 32.95%	806,911 $65.5 Million
Q4 2018 Feb 14, 2019	BUY	$43.37 - $59.54 $13 Million - $17.8 Million	298,700 Added 96.91%	606,911 $32.8 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $11.2 Million - $14 Million	260,700 Added 548.72%	308,211 $15.9 Million
Q2 2018 Aug 14, 2018	SELL	$40.53 - $50.7 $4.7 Million - $5.88 Million	-116,000 Reduced 70.94%	47,511 $1.98 Million
Q1 2018 May 15, 2018	BUY	$44.08 - $55.05 $775,808 - $968,880	17,600 Added 12.06%	163,511 $7.21 Million
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $5.53 Million - $7.08 Million	110,000 Added 306.31%	145,911 $7.34 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $1.64 Million - $2.14 Million	35,911	35,911 $1.82 Million

Others Institutions Holding IONS

# of Institutions

396

Shares Held

122M

Call Options Held

854K

Put Options Held

464K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $6.76B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account